Emalex Biosciences

Emalex Biosciences company information, Employees & Contact Information

Updated May 2026

Quick answer

Emalex Biosciences is a Biotechnology Research company and founded in 2018. It has approximately 39 employees on record. Contact data was last refreshed in May 2026. Find Emalex Biosciences's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Emalex Biosciences is in late-stage development for a new class of drug for patients with Tourette syndrome and other neurological disorders.

Company Details

Employees
39
Founded
2018
Address
330 N Wabash Ave,
Email
em****@****ces.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Chicago, Illinois
Looking for a particular Emalex Biosciences employee's phone or email?

Emalex Biosciences Questions

News

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization - Yahoo Finance

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization Yahoo Finance

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome - Bain Capital

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome Bain Capital

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study - Yahoo Finance

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study Yahoo Finance

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials - PR Newswire

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials PR Newswire

Ecopipam Meets Primary and Secondary End Points in Phase 3 Study for Tourette Syndrome - NeurologyLive

Ecopipam Meets Primary and Secondary End Points in Phase 3 Study for Tourette Syndrome NeurologyLive

New Positive 12-Month Extension Data: Ecopipam for Tourette Syndrome in Pediatric Patients - Psychiatric Times

New Positive 12-Month Extension Data: Ecopipam for Tourette Syndrome in Pediatric Patients Psychiatric Times

Paragon’s Portfolio Company – Emalex Biosciences – Raises $250 Million in Series D Financing to Fund Tourette’s Clinical Trial - BOSS Publishing

Paragon’s Portfolio Company – Emalex Biosciences – Raises $250 Million in Series D Financing to Fund Tourette’s Clinical Trial BOSS Publishing

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome - PR Newswire

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome PR Newswire

Top Emalex Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant